Response Genetics, Inc RGDXQ

Company Overview

Response Genetics, Inc. (OTC: RGDXQ) was a molecular diagnostics company focused on cancer testing and personalized medicine. The company developed and commercialized diagnostic assays intended to help physicians tailor oncology treatments based on a patient’s genetic profile. Its operations were centered on molecular profiling technologies used to evaluate biomarkers associated with chemotherapy response and disease progression, primarily within the oncology sector.

The company’s principal revenue drivers historically included laboratory testing services, biomarker analysis, and companion diagnostic-related activities for cancer care providers and pharmaceutical collaborators. Response Genetics served oncologists, hospitals, clinical laboratories, and biopharmaceutical companies involved in cancer therapeutics development. The company was founded in 2000 and expanded during the growth of precision medicine and pharmacogenomics in oncology. Public filings and market records indicate that the company later experienced financial distress, ultimately entering bankruptcy proceedings, after which its shares traded on the over-the-counter market under the symbol RGDXQ.